Streetbeat News

Products Services

GME

GameStop (NYSE:GME) is anticipated to report Q4 earnings with a focus on profitability and Ryan Cohen's new role in investing company cash. Analysts expect $2.05 billion in revenue and earnings per share of 29 cents. A significant development is the Board's decision to allow investments in equity securities, overseen by CEO Ryan Cohen, which has been criticized by analysts. Investors are keen on GameStop's investment decisions, future growth opportunities, and the potential impact of digital sales shifts on the company.

Portfolio Pulse from Chris Katje

March 25, 2024 | 4:39 pm

BYDDY

DRIV

NIO

TSLA

Tesla Inc (TSLA) is adjusting its strategy to focus on profitability over volume, with price increases for the Model Y in the U.S. and Eurozone amid reports of slowing production in China due to competition and slowing EV sales. Analysts at Oppenheimer believe this shift towards maximizing value per vehicle and leveraging software updates, particularly in Full Self-Driving, could enhance revenue. However, Tesla's stock has declined nearly 32% in 2024, while the Global X Autonomous & Electric Vehicles ETF (DRIV) remains flat. Oppenheimer maintains a Perform market rating for Tesla, highlighting its potential as a transformational technology company.

Portfolio Pulse from Neil Dennis

March 25, 2024 | 4:08 pm

AXSM

Axsome Therapeutics Inc (NASDAQ:AXSM) announced positive results from the SYMPHONY Phase 3 trial of AXS-12 in narcolepsy patients, showing significant improvements in cataplexy attacks, excessive daytime sleepiness, and other symptoms compared to placebo. Despite the positive trial results, AXSM shares dropped 3.84% to $77.56.

Portfolio Pulse from Vandana Singh

March 25, 2024 | 4:08 pm

DOW

Dow Chemical Company (NYSE:DOW) announced its plan to invest in a new world-scale carbonate solvents facility in the U.S. Gulf Coast to support the electric vehicle (EV) and energy storage markets. This facility, selected for award negotiations by the U.S. Department of Energy, aims to capture over 90% of CO2 from its manufacturing process, aligning with Dow's decarbonization strategy and the U.S. government's goals to reduce greenhouse gas emissions. The project is backed by agreements with leading EV manufacturers and electrolyte manufacturers, enhancing Dow's MobilityScience portfolio.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 4:08 pm

NFLX

A significant number of investors have shown a bearish stance on Netflix (NASDAQ:NFLX), as evidenced by unusual options trading activity. Benzinga's options scanner revealed 38 uncommon trades, with a sentiment split between 42% bullish and 57% bearish. The trades suggest a price target range of $300 to $700 for Netflix in the short term. The company, known for its streaming service, has nearly 250 million subscribers globally and has recently introduced ad-supported subscription plans. Despite the bearish options activity, expert opinions remain positive, with an average target price of $683 and ratings ranging from Neutral to Buy.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:08 pm

RCUS

Arcus Biosciences (NYSE:RCUS) received mixed analyst ratings with 2 bullish and 3 somewhat bullish out of 5 total. The average 12-month price target was adjusted to $37.6, down 13.56% from previous estimates. Analysts from Truist Securities and Wedbush maintained their ratings, while Mizuho lowered its price target. The company, a clinical-stage biopharmaceutical firm focusing on cancer immunotherapies, showed a revenue decline of -8.82% and a net margin of -261.29%, indicating financial challenges.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:08 pm

CMP

Compass Minerals' stock is trading lower following the announcement that the U.S. Forest Service will not contract the company for magnesium chloride-based aerial fire retardants for the 2024 fire season.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 4:08 pm

REGN

The FDA has delayed approval for Regeneron Pharmaceuticals Inc's odronextamab, a treatment for blood cancer, requesting additional trial data. Despite no issues with clinical efficacy or safety, the FDA seeks more information from ongoing Phase 3 trials. This delay is not expected to significantly impact Regeneron's overall performance, as the drug's market potential is limited. Regulatory review by the EMA is still in progress.

Portfolio Pulse from Vandana Singh

March 25, 2024 | 4:07 pm

F

GM

HMC

NSANY

TSLA

Nissan Motor Co Ltd (OTC:NSANY) announced the launch of 30 new models over the next three years, with 16 being electrified, in response to the rapid developments in the EV industry. This move contrasts with other automakers like Tesla Inc (NASDAQ:TSLA), Ford Motor (NYSE:F), and General Motors (NYSE:GM), which are bracing for cooling EV demand. Nissan aims to sell an additional 1 million vehicles by fiscal year 2026, targeting an operating profit margin of over 6% and total shareholder returns of over 30%. The company is also exploring a strategic partnership with Honda Motor Co Ltd (NYSE:HMC) to produce key EV components and develop AI in automotive software platforms.

Portfolio Pulse from Upwallstreet

March 25, 2024 | 4:07 pm

MBRX

Moleculin Biotech's shares dropped following a preliminary update on its lead program MB-106 for Acute Myeloid Leukemia and the announcement of its FY23 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 4:07 pm